Gefitinib, a targeted therapy for non-small cell lung cancer (NSCLC), has become a critical medication in oncology. Originally marketed under the brand name Iressa, the availability of generic Gefitinib has made this life-saving drug more affordable and accessible. Key exporters of Gefitinib play an essential role in distributing the medication to international markets, ensuring patients worldwide can benefit from its therapeutic effects.
Prominent Gefitinib exporter (https://www.specialitymedz.com/product/gefitinib-manufacturer/) include leading pharmaceutical companies such as Natco Pharma, Dr. Reddy's Laboratories, Cipla, and Sun Pharmaceutical Industries. These companies are known for their stringent quality control and adherence to international standards, ensuring that their exported products meet the regulatory requirements of countries across Asia, Africa, Europe, and Latin America.
Gefitinib is typically exported in multiple strengths, such as 250 mg tablets, to cater to varying patient needs. Exporters work closely with global distributors, healthcare providers, and local governments to make the drug accessible in regions where advanced cancer treatments are in high demand but often unaffordable.